MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

3.54 3.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.43

Максимум

3.63

Ключови измерители
By Trading Economics
Приходи	48M -8.9M
Продажби	36M 45M
Марж на печалбата	-19.942
Служители	562
EBITDA	22M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+107.27% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	121M 1B
Предишно отваряне	0.33
Предишно затваряне	3.54

Настроения в новините

By Acuity

61%

39%

304 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.99 / 2.635 Подкрепа & съпротива

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.04.2026 г., 23:07 ч. UTC

Пазарно говорене

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9.04.2026 г., 22:54 ч. UTC

Пазарно говорене

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9.04.2026 г., 20:57 ч. UTC

Значими събития в новините

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.04.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Rowan Digital Infrastructure Announces Strategic Recapitalization

9.04.2026 г., 20:25 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.04.2026 г., 19:30 ч. UTC

Значими събития в новините

How Digital Currencies Have Helped Iran -- WSJ

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

107.27% нагоре

12-месечна прогноза

Среден 7.13 USD 107.27%

Висок 11 USD

Нисък 3.52 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

304 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.